Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CHECKvacc (CF33-hNIS-antiPDL1) / Imugene
NCT05081492: CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer	Active, not recruiting	1	9	US	Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody, CF33 Expressing hNIS-Anti-PD-L1 Antibody, CF33-hNIS-antiPDL1	City of Hope Medical Center, National Cancer Institute (NCI), Imugene Limited	Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8	09/24	09/24